Aromatase inhibitors, estrogens and musculoskeletal pain: Estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Liu, Mohan ^a   Wang, Liewei ^a   Bongartz, Tim ^b   Hawse, John R ^a   Markovic, Svetomir N ^b   Schaid, Daniel J ^b   Mushiroda, Taisei ^c   Kubo, Michiaki ^c   Nakamura, Yusuke ^c   Kamatani, Naoyuki ^c   Goss, Paul E ^d   Ingle, James N ^b   Weinshilboum, Richard M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c RIKEN   (Japan)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOKINE RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 17; INTERLEUKIN 18 RECEPTOR; MESSENGER RNA; T CELL LEUKEMIA 1A PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; ESTROGEN RECEPTOR ALPHA, HUMAN; IL12RB2 PROTEIN, HUMAN; IL17RA PROTEIN, HUMAN; IL1R2 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 17 RECEPTOR; ONCOPROTEIN; TCL1A PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; FUNCTIONAL GENOMICS; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; CELL LINE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; METABOLISM;

AROMATASE INHIBITORS; CELL LINE; CYTOKINES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; MUSCULOSKELETAL PAIN; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RECEPTORS, INTERLEUKIN-1 TYPE II; RECEPTORS, INTERLEUKIN-12; RECEPTORS, INTERLEUKIN-17;

EID: 84862797634     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3137     Document Type: Article

References (31)

1. Del Mastro L, Clavarezza M, Venturini M. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors. Cancer Treat Rev 2007, 33:681-687. 10.1016/j.ctrv.2007.07.014, 17850976.
2. Khan QJ, O'Dea AP, Sharma P. Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol 2010, pii: 654348.
3. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16:223-234. 10.1016/j.breast.2007.01.011, 17368903.
4. Cecil RL, Archer BH. Arthritis and the menopause. J Am Med Assoc 1925, 84:75-79.
5. Brunner RL, Aragaki A, Barnabei V, Cochrane BB, Gass M, Hendrix S, Lane D, Ockene J, Woods NF, Yasmeen S, Stefanick M. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010, 17:946-954. 10.1097/gme.0b013e3181d76953, 20505547.
6. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682. 10.1200/JCO.2010.28.5064, 3020700, 20876420.
7. Fu TB, Virgilio L, Narducci MG, Facchiano A, Russo G, Croce CM. Characterization and localization of the TCL-1 oncogene product. Cancer Res 1994, 54:6297-6301.
8. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009, 114:4675-4686. 10.1182/blood-2009-03-208256, 2780304, 19770358.
9. Kunstle G, Laine J, Pierron G, Kagami Si S, Nakajima H, Hoh F, Roumestand C, Stern MH, Noguchi M. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002, 22:1513-1525. 10.1128/MCB.22.5.1513-1525.2002, 134690, 11839817.
10. Laine VJ, Grass DS, Nevalainen TJ. Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection. Infect Immun 2000, 68:87-92. 10.1128/IAI.68.1.87-92.2000, 97105, 10603372.
11. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene 2001, 20:5638-5643. 10.1038/sj.onc.1204596, 11607815.
12. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, Wu TY, Jenkins GD, Batzler A, Wang L. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010, 20:482-492. 2963812, 20923822.
13. Gene Expression Omnibus. , http://www.ncbi.nih.gov/geo
14. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009, 69:1722-1727. 10.1158/0008-5472.CAN-08-3933, 19244106.
15. Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. Cancer Res 2010, 70(24 Suppl):75s.
16. Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006, 11:718-731. 10.1634/theoncologist.11-7-718, 16880231.
17. Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?. Clin Breast Cancer 2009, 9:34-38. 10.3816/CBC.2009.n.006, 19299238.
18. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
19. Okamoto T. NF-κB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006, 6:359-372.
20. Levin SD. IL-17 receptor signaling: ubiquitin gets in on the act. Sci Signal 2009, 2:pe64. 10.1126/scisignal.292pe64, 19825826.
21. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000, 6:395-407. 10.1016/S1097-2765(00)00039-3, 10983986.
22. Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-κB pathway. Biochem Pharmacol 2008, 75:1515-1525. 10.1016/j.bcp.2007.12.014, 18243161.
23. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 2005, 16:46-52. 10.1016/j.tem.2005.01.004, 15734144.
24. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 2005, 18:71-82. 10.1016/j.molcel.2005.03.006, 15808510.
25. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010, 70:3278-3286. 10.1158/0008-5472.CAN-09-3024, 2855746, 20354183.
26. Ingle JN. Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids 2011, 76:765-767. 10.1016/j.steroids.2011.02.021, 21382394.
27. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 2007, 14:89-96. 10.3747/co.2007.117, 1899358, 17593981.
28. Hoyer KK, Herling M, Bagrintseva K, Dawson DW, French SW, Renard M, Weinger JG, Jones D, Teitell MA. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol 2005, 175:864-873.
29. Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, Russo G, Tsichlis P, Croce CM. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000, 97:3028-3033. 10.1073/pnas.040557697, 16186, 10716693.
30. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol 2010, 176:2139-2149. 10.2353/ajpath.2010.090477, 2861080, 20228224.
31. Toh M-L, Kawashima M, Hot A, Miossec P, Miossec P. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rβ2 inhibition. Ann Rheum Dis 2010, 69:1562-1567. 10.1136/ard.2009.111757, 20542964.